Sanoculis
Yokneam, Israel· Est.
Israeli medtech firm delivering stent‑free minimally invasive glaucoma surgery devices.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Funding information not available
AI Company Overview
Israeli medtech firm delivering stent‑free minimally invasive glaucoma surgery devices.
Ophthalmology
Technology Platform
Stent‑less, minimally invasive micro‑trephination devices that create precise drainage pathways in the trabecular meshwork to lower intra‑ocular pressure.
Opportunities
Expansion into the US market, growing adoption of MIGS procedures, and potential for bundled cataract‑glaucoma surgery offerings.
Risk Factors
Regulatory clearance delays, reimbursement uncertainty, and competition from established implantable MIGS devices.
Competitive Landscape
Competes with implant‑based MIGS devices such as iStent, Hydrus, and Xen Gel Stent; differentiates through a stent‑free, lower‑cost, and potentially safer surgical approach.